Meeting
Abstract Number: O2
SHM Converge 2022
Case Presentation: A 73-year-old woman with past medical history of metastatic endometrial adenocarcinoma previously treated with Pembrolizumab (stopped 4 months prior) presented with six weeks of persistent fatigue, myalgias, nausea, and vomiting. On presentation, she was noted to be hypotensive with labs notable for hyponatremia and hypomagnesemia. She appeared lethargic with dry mucous membranes and […]
Abstract Number: C37
SHM Converge 2022
Case Presentation: A 78-year-old gentleman with a past medical history of scalp melanoma, renal papillary cell carcinoma, Ewing sarcoma, and end-stage renal disease presented to an outpatient Oncology appointment with bilateral ptosis, diplopia, myalgias, and bilateral proximal leg weakness less than one week following pembrolizumab infusion and influenza vaccination. He was sent to outpatient Neurology […]
Abstract Number: E32
SHM Converge 2022
Case Presentation: A 67-year-old woman with a history of metastatic squamous cell carcinoma of the lungs and plaque psoriasis presented with subacute pruritic and painful descaling lesions of the skin after pembrolizumab maintenance therapy (Figure 1.A). The lesions on the skin were erythematous and desquamating, worse in the upper extremities, lower extremities, abdomen, and trunk. […]
Abstract Number: L46
SHM Converge 2022
Case Presentation: Immune checkpoint inhibitors have evolved into the conventional therapy regimen for many cancer types. The major categories of immune checkpoint inhibitors include monoclonal antibodies against cytotoxic T lymphocyte antigen (CTLA-4), programmed cell death protein-1 (PD-1) and programmed cell death ligand molecules (PD-L1). Pembrolizumab has been implicated in causing hepatitis Discussion: An 89-year-old Caucasian […]